Torrent Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
2865.80 +26.15 (0.92%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2798.25
Today’s High
2879
52 Week Low
1771.35
52 Week High
2977.1
2869.00 +31.50 (1.11%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2799.85
Today’s High
2880
52 Week Low
1772.05
52 Week High
2980
Key Metrics
- Market Cap (In Cr) 96033.89
- Beta 0.46
- Div. Yield (%) 0.99
- P/B 14.01
- TTM P/E 53.14
- Peg Ratio 2.51
- Sector P/E 31.74
- D/E 0.59
- Open Price 2840.05
- Prev Close 2839.65
Torrent Pharmaceuticals Analysis
Price Analysis
-
1 Week1.68%
-
3 Months9.61%
-
6 Month20.67%
-
YTD23.07%
-
1 Year51.11%
Risk Meter
- 23% Low risk
- 23% Moderate risk
- 23% Balanced Risk
- 23% High risk
- 23% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 9
- 9
- 9
- 8
- Buy
- 12
- 12
- 12
- 12
- Hold
- 4
- 4
- 4
- 4
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 27
- 27
- 27
- 26
Torrent Pharmaceuticals News
Torrent Pharmaceuticals, Avenue Supermarts & others hit 52 week high today ; Do you own any?
3 min read . 19 Jun 2024Dividend Stocks: Tata Steel, L&T, Cyient, others to trade ex-dividend next week
4 min read . 15 Jun 2024Torrent Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 10728
- Selling/ General/ Admin Expenses Total
- 1984
- Depreciation/ Amortization
- 808
- Other Operating Expenses Total
- 2690
- Total Operating Expense
- 8080
- Operating Income
- 2648
- Net Income Before Taxes
- 2352
- Net Income
- 1656
- Diluted Normalized EPS
- 47.11
- Period
- 2024
- Total Assets
- 15061
- Total Liabilities
- 8205
- Total Equity
- 6856
- Tangible Book Valueper Share Common Eq
- 57.17
- Period
- 2024
- Cashfrom Operating Activities
- 3266
- Cashfrom Investing Activities
- -168
- Cashfrom Financing Activities
- -2779
- Net Changein Cash
- 327
- Period
- 2023
- Total Revenue
- 9620.15
- Selling/ General/ Admin Expenses Total
- 3447.24
- Depreciation/ Amortization
- 702.03
- Other Operating Expenses Total
- 471.9
- Total Operating Expense
- 7484.69
- Operating Income
- 2135.46
- Net Income Before Taxes
- 1847.16
- Net Income
- 1245.23
- Diluted Normalized EPS
- 36.45
- Period
- 2023
- Total Assets
- 15011.85
- Total Liabilities
- 8813.78
- Total Equity
- 6198.07
- Tangible Book Valueper Share Common Eq
- 22.78
- Period
- 2023
- Cashfrom Operating Activities
- 2426.96
- Cashfrom Investing Activities
- -2415.31
- Cashfrom Financing Activities
- 77.36
- Net Changein Cash
- 110.13
- Period
- 2022
- Total Revenue
- 8508.04
- Selling/ General/ Admin Expenses Total
- 3060.61
- Depreciation/ Amortization
- 661.93
- Other Operating Expenses Total
- 440.04
- Total Operating Expense
- 7223.63
- Operating Income
- 1284.41
- Net Income Before Taxes
- 1225.91
- Net Income
- 777.18
- Diluted Normalized EPS
- 32.05
- Period
- 2022
- Total Assets
- 13099.84
- Total Liabilities
- 7146.89
- Total Equity
- 5952.95
- Tangible Book Valueper Share Common Eq
- 63.45
- Period
- 2022
- Cashfrom Operating Activities
- 1802.99
- Cashfrom Investing Activities
- -196.63
- Cashfrom Financing Activities
- -1781.05
- Net Changein Cash
- -174.16
- Period
- 2021
- Total Revenue
- 8004.83
- Selling/ General/ Admin Expenses Total
- 2822.98
- Depreciation/ Amortization
- 657.31
- Other Operating Expenses Total
- 435.69
- Total Operating Expense
- 6176.94
- Operating Income
- 1827.89
- Net Income Before Taxes
- 1526.26
- Net Income
- 1251.88
- Diluted Normalized EPS
- 37
- Period
- 2021
- Total Assets
- 14074.65
- Total Liabilities
- 8237.48
- Total Equity
- 5837.17
- Tangible Book Valueper Share Common Eq
- 44.67
- Period
- 2021
- Cashfrom Operating Activities
- 2005.35
- Cashfrom Investing Activities
- -449.42
- Cashfrom Financing Activities
- -1650.79
- Net Changein Cash
- -89.26
- Period
- 2020
- Total Revenue
- 7939.31
- Selling/ General/ Admin Expenses Total
- 2908.94
- Depreciation/ Amortization
- 651.51
- Other Operating Expenses Total
- 514.98
- Total Operating Expense
- 6423.33
- Operating Income
- 1515.98
- Net Income Before Taxes
- 1186.57
- Net Income
- 1024.72
- Diluted Normalized EPS
- 28.79
- Period
- 2020
- Total Assets
- 14009.74
- Total Liabilities
- 9186.52
- Total Equity
- 4823.22
- Tangible Book Valueper Share Common Eq
- 3.19
- Period
- 2020
- Cashfrom Operating Activities
- 1392.91
- Cashfrom Investing Activities
- 198.61
- Cashfrom Financing Activities
- -1549.04
- Net Changein Cash
- 73.06
- Period
- 2019
- Total Revenue
- 7672.8
- Selling/ General/ Admin Expenses Total
- 2897.84
- Depreciation/ Amortization
- 614.39
- Other Operating Expenses Total
- 470.23
- Total Operating Expense
- 6664.44
- Operating Income
- 1008.36
- Net Income Before Taxes
- 561.66
- Net Income
- 436.28
- Diluted Normalized EPS
- 21.16
- Period
- 2019
- Total Assets
- 14120.92
- Total Liabilities
- 9396.57
- Total Equity
- 4724.35
- Tangible Book Valueper Share Common Eq
- -10.65
- Period
- 2019
- Cashfrom Operating Activities
- 1798.08
- Cashfrom Investing Activities
- -241.28
- Cashfrom Financing Activities
- -1314.45
- Net Changein Cash
- 238.02
- Period
- 2018
- Total Revenue
- 5949.83
- Selling/ General/ Admin Expenses Total
- 2421.14
- Depreciation/ Amortization
- 408.6
- Other Operating Expenses Total
- 402.62
- Total Operating Expense
- 5009.18
- Operating Income
- 940.65
- Net Income Before Taxes
- 931.01
- Net Income
- 678.11
- Diluted Normalized EPS
- 20.04
- Period
- 2018
- Total Assets
- 14243.22
- Total Liabilities
- 9621.03
- Total Equity
- 4622.19
- Tangible Book Valueper Share Common Eq
- -30.71
- Period
- 2018
- Cashfrom Operating Activities
- 899.42
- Cashfrom Investing Activities
- -4706.95
- Cashfrom Financing Activities
- 3417.39
- Net Changein Cash
- -365.5
- Period
- 2024-03-31
- Total Revenue
- 2745
- Selling/ General/ Admin Expenses Total
- 486
- Depreciation/ Amortization
- 203
- Other Operating Expenses Total
- 697
- Total Operating Expense
- 2065
- Operating Income
- 680
- Net Income Before Taxes
- 631
- Net Income
- 449
- Diluted Normalized EPS
- 13.27
- Period
- 2024-03-31
- Total Assets
- 15061
- Total Liabilities
- 8205
- Total Equity
- 6856
- Tangible Book Valueper Share Common Eq
- 57.17
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 3266
- Cashfrom Investing Activities
- -168
- Cashfrom Financing Activities
- -2779
- Net Changein Cash
- 327
- Period
- 2023-12-31
- Total Revenue
- 2732
- Selling/ General/ Admin Expenses Total
- 496
- Depreciation/ Amortization
- 213
- Other Operating Expenses Total
- 670
- Total Operating Expense
- 1988
- Operating Income
- 744
- Net Income Before Taxes
- 631
- Net Income
- 443
- Diluted Normalized EPS
- 11.27
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 2660
- Selling/ General/ Admin Expenses Total
- 503
- Depreciation/ Amortization
- 201
- Other Operating Expenses Total
- 672
- Total Operating Expense
- 2036
- Operating Income
- 624
- Net Income Before Taxes
- 559
- Net Income
- 386
- Diluted Normalized EPS
- 11.39
- Period
- 2023-09-30
- Total Assets
- 14744
- Total Liabilities
- 8037
- Total Equity
- 6707
- Tangible Book Valueper Share Common Eq
- 45.21
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 1540
- Cashfrom Investing Activities
- -166
- Cashfrom Financing Activities
- -1344
- Net Changein Cash
- 30
- Period
- 2023-06-30
- Total Revenue
- 2591
- Selling/ General/ Admin Expenses Total
- 499
- Depreciation/ Amortization
- 191
- Other Operating Expenses Total
- 651
- Total Operating Expense
- 1991
- Operating Income
- 600
- Net Income Before Taxes
- 531
- Net Income
- 378
- Diluted Normalized EPS
- 11.18
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 2491.15
- Selling/ General/ Admin Expenses Total
- 440.69
- Depreciation/ Amortization
- 195.59
- Other Operating Expenses Total
- 619.22
- Total Operating Expense
- 1959.69
- Operating Income
- 531.46
- Net Income Before Taxes
- 433.16
- Net Income
- 296.23
- Diluted Normalized EPS
- 8.77
- Period
- 2023-03-31
- Total Assets
- 15011.85
- Total Liabilities
- 8813.78
- Total Equity
- 6198.07
- Tangible Book Valueper Share Common Eq
- 22.78
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2426.96
- Cashfrom Investing Activities
- -2415.31
- Cashfrom Financing Activities
- 77.36
- Net Changein Cash
- 110.13
- Period
- 2022-12-31
- Total Revenue
- 2491
- Selling/ General/ Admin Expenses Total
- 423
- Depreciation/ Amortization
- 193
- Other Operating Expenses Total
- 614
- Total Operating Expense
- 1960
- Operating Income
- 531
- Net Income Before Taxes
- 419
- Net Income
- 283
- Diluted Normalized EPS
- 8.36
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Torrent Pharmaceuticals Technical
Moving Average
SMA
- 5 Day2790.68
- 10 Day2819.81
- 20 Day2827.52
- 50 Day2726.79
- 100 Day2669.48
- 300 Day2385.55
Torrent Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Zydus Lifesciences
- 1137.2
- 42.55
- 3.89
- 1171.95
- 564.05
- 114402.32
- Dr Reddys Laboratories
- 6476.7
- 48.65
- 0.76
- 6524.95
- 5042.65
- 107855.5
- Torrent Pharmaceuticals
- 2865.8
- 26.15
- 0.92
- 2977.1
- 1771.35
- 96995.87
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40512.13
- Alkem Laboratories
- 4970
- -2
- -0.04
- 5581.2
- 3440.05
- 59416.35
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Zydus Lifesciences
- 28.26
- 5.45
- 15.65
- 14.33
- Dr Reddys Laboratories
- 19.45
- 3.75
- 16.73
- 14.63
- Torrent Pharmaceuticals
- 59.52
- 13.92
- 20.64
- 13.18
- Lupin
- 39
- 5.21
- 2.51
- 2.04
- Alkem Laboratories
- 32.76
- 5.7
- 18.26
- 13.94
Torrent Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 24-May-24
- Audited Results & Final Dividend
- 02-Feb-24
- Quarterly Results & Interim Dividend
- 23-Oct-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results & Final Dividend
- 25-Jan-23
- Quarterly Results & Interim Dividend
- 21-Oct-22
- Quarterly Results
- 29-Jul-22
- Quarterly Results
- 25-May-22
- Audited Results, Dividend & Bonus issue
- 25-Jan-22
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 29-Nov-23
- 26-Oct-23
- POM
- 07-Aug-23
- 20-Jun-23
- AGM
- 29-Jul-22
- 25-May-22
- AGM
- 27-Jul-21
- 30-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 24-May-24
- 21-Jun-24
- 21-Jun-24
- 6
- 12-Jan-24
- 12-Feb-24
- 12-Feb-24
- 22
- 30-May-23
- 23-Jun-23
- 23-Jun-23
- 8
- 12-Jan-23
- 03-Feb-23
- 03-Feb-23
- 14
- 25-May-22
- 06-Jun-22
- 03-Jun-22
- 8
- 26-May-22
- 06-Jun-22
- 03-Jun-22
- 15
- 10-Jan-22
- 03-Feb-22
- 02-Feb-22
- 25
- 18-May-21
- 18-Jun-21
- 17-Jun-21
- 15
- 18-Jan-21
- 16-Feb-21
- 15-Feb-21
- 20
- Announced on
- Record Date
- Ex-Bonus
- Description
- 25-May-22
- 11-Jul-22
- 08-Jul-22
- Bonus issue of equity shares in the ratio of 1:1 of Rs. 5/-.
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)